TL1A HLE / Vial - LARVOL DELTA

A First-in-Human Study of BB-TL1A-VIAL-HLE in Healthy Adults and People With Ulcerative Colitis (clinicaltrials.gov) - P1 | N=16 | Terminated | Sponsor: Vial Australia Pty Ltd | N=34 ➔ 16 | Trial completion date: Dec 2026 ➔ Dec 2025 | Recruiting ➔ Terminated; Study terminated based on interim analysis results indicating the primary pharmacokinetic endpoint was unlikely to be met.

Enrollment change • First-in-human • Trial completion date • Trial termination • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A First-in-Human Study of BB-TL1A-VIAL-HLE in Healthy Adults and People With Ulcerative Colitis (clinicaltrials.gov) - P1 | N=34 | Recruiting | Sponsor: Battery Bio Australia Pty Ltd | N=54 ➔ 34

Enrollment change • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A First-in-Human Study of BB-TL1A-VIAL-HLE in Healthy Adults and People With Ulcerative Colitis (clinicaltrials.gov) - P1 | N=54 | Recruiting | Sponsor: Battery Bio Australia Pty Ltd

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis